ProKidney Corp. (PROK) Stock

ProKidney Corp. (PROK) is a Healthcare stock trading at $1.62 (as of 2026-08-21), with a market capitalization of $99.70M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ProKidney Corp. is a clinical-stage biotechnology company developing cellular therapy candidates. Its pipeline includes an autologous renal cell therapy in Phase III development and additional clinical studies in diabetic kidney disease and congenital anomalies of the kidney and urinary tract.

Understand ProKidney Corp.: how it makes money

ProKidney Corp. develops autologous cellular therapy candidates for kidney diseases, including Renal Autologous Cell Therapy in a Phase III program and additional Phase II and Phase I studies, with progress in these trials driving future value.

For ProKidney, the profit model is mostly a clinical execution and approval bet, because its lead Renal Autologous Cell Therapy program (Phase III PROACT 1) needs to demonstrate efficacy and move through regulatory milestones before commercialization can generate revenue.

Business quality (Weak): This is a clinical-stage biotechnology company, so the most decision-relevant signals in the provided data are trial design and efficacy-related study metrics, not operating financial results.

Bull case

  • Lead asset is already in Phase III (PROACT 1) for Renal Autologous Cell Therapy: The Phase III program is set with Planned Enrollment (Phase 3 PROACT 1) of 470.0 and Study Power (Phase 3 PROACT 1) of 90.0.
  • Phase 2 efficacy signals reported in the provided metrics: Phase 2 REGEN-007 Group 1 shows an Improvement in Annual Decline in eGFR Slope (Phase 2 REGEN-007, Group 1) of 4.6 and Percent Improvement in Estimated Glomerular Filtration Rate Slope (Group 1) of 78.0.

Bear case

  • No revenue is shown in the provided quarter data, so operating economics are likely not yet established: For the period 2026-03-31, revenue_b is 0.0 and operating_margin_pct is -19881.9.
  • Phase 2 results do not uniformly show the strongest statistical signal across groups: Phase 2 REGEN-007 Group 2 lists Statistical Significance of Difference in Estimated Glomerular Filtration Rate Slope (Group 2, P-Value) as 0.09.
Valuation — source: SEC EDGAR (first-party)
Price$1.62
Market Cap$99.70M
Price / Sales121.88
FCF Yield-160.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$893000.00
Net Margin-7725.2%
Revenue Growth (YoY)-32.1%
FCF Growth (YoY)28.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.98 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSUVRETTA CAPITAL MANAGEMENT, LLC ($22.09M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOBruce Culleton
Employees204
CountryUS
IPO Date2021-06-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • TScan Therapeutics, Inc. (TCRX)
  • Kalaris Therapeutics Inc (KLRS)
  • Atara Biotherapeutics, Inc. (ATRA)
  • Cognition Therapeutics, Inc. (CGTX)
  • Outlook Therapeutics, Inc. (OTLK)
  • Champions Oncology, Inc. (CSBR)
  • Cardiff Oncology, Inc. (CRDF)
  • ImageneBio Inc (IMA)
PROK earnings history · PROK institutional & insider holders · PROK KPIs & operating metrics · PROK financials · PROK investor presentations & press releases · PROK SEC filings · PROK peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.